Ocumension Therapeutics

5DG

Company Profile

  • Business description

    Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

  • Contact

    No. 1858 Yinzhongnan Road
    Guoxiang Subdistrict
    Wuzhong District
    SuzhouJiangsu
    CHN

    T: +86 2161493800

    https://www.ocumension.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    489

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,877.66110.951.43%
DAX 4024,562.44355.531.47%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,860.326.140.07%
HKSE23,892.32255.75-1.06%
NASDAQ20,418.465.950.03%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.520.000.00%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers